anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Rett syndrome (RTT) is a rare neurodevelopmental disorder with developmental impairments, comorbidities, and abnormal behaviours such as hand stereotypies and emotional features. The Rett Syndrome Behaviour Questionnaire (RSBQ) was developed to describe the behavioural and emotional features of RTT. Little is known how RSBQ scores are associated with genetic and clinical characteristics in RTT. This study investigated relationships between genotype, age, walking, hand function, sleep, and RSBQ total and subscale scores in RTT.
METHODS: This is a cross-sectional analysis of data collected in the Australian Rett Syndrome Database and the International Rett Syndrome Phenotype Database. Parent caregivers completed the RSBQ and Sleep Disturbance Scale for Children [subscales for disorders of initiating and maintaining sleep (DIMS), disorders of excessive somnolence (DOES)], and provided information on age, variant type, functional abilities (mobility, hand function), seizure frequency and gastrointestinal problems. Associations between the RSBQ scores and the independent variables were modelled using linear regression.
RESULTS: Data were available for 365 individuals with RTT [median (range) age 17.8 (2.9-51.9) years, 2 males]. Compared to adults, 2- to 12-year-old children had higher mean Total, Night-time Behaviour and Fear/Anxiety scores. Compared to individuals with a C-terminal deletion, individuals with the p.Arg255* variant had higher mean Total and Night-time Behaviours scores, whereas the p.Arg294* variant had higher mean Mood scores. Individuals with intermediate mobility and hand function abilities had a higher mean Total score. Total RSBQ and subscale scores were similar across categories for seizures, constipation, and reflux, but were higher with abnormal DIMS and abnormal DOES scores.
CONCLUSION: Except for associations with sleep, the RSBQ measures the behavioural phenotype rather than clinical severity in RTT, as traditionally conceptualised in terms of functional abilities and comorbidities. When designing clinical trials, the RSBQ needs to be complemented by other outcome measures to assess specific core functions and associated comorbidities in RTT.
The invention discloses a method for inhibiting growth and metastasis of hepatocellular carcinoma by using secretion components of exosomes generated by tumor macrophages regulated by interleukin 2(IL-2), which explores the influence of exosomes from TAM and IL-2 on liver cancer development. TAM was collected and cultured from liver cancer tissues. With IL-2 (Exo) IL2‑TAM ) Or unused (Exo) TAM ) Exosomes of treated TAMs, and are useful for treating liver cancer. Detecting liver cancer cell proliferation, apoptosis and metastasis in vivo and in vitro. In vivo and in vitro, with Exo TAM In contrast, Exo IL2‑TAM Treatment was observed to decrease cell proliferation and metastasis as well as increase apoptosis. IL-2 can modulate the exosome component from TAM to ameliorate the development of hepatocellular carcinoma. The invention provides a new visual angle and a new method for a mechanism of IL-2 inhibiting hepatocellular carcinoma, and suggests the potential clinical value of exosome components released by TAMs.
PURPOSE: To present a novel technique of preperitoneal cross-over for eTEP VHR.
METHODS: Patients who underwent robotic eTEP with mesh utilizing a preperitoneal cross over technique were identified using a single-institution hernia database. This novel technique involves minimally invasive access to the retro-rectus space on one side with midline cross over into the preperitoneal space on the contralateral side. Baseline demographics of the patients were obtained, and intra-operative and post-operative outcomes were reported.
RESULTS: Nine VHR patients underwent robotic eTEP with mesh using a preperitoneal crossover technique. Five patients were male, mean age was 53 ± 18.4 years, and mean BMI was 32.5 ± 4.2 kg/m2. Two patients were diabetic and 2 were previous smokers. Two of the hernias were recurrent. The average hernia defect was 96.9 ± 45.5 cm2 and the average mesh size was 593.3 ± 168.2 cm2. Four patients underwent a unilateral TAR, while five patients did not require any component separation. All cases were CDC Class 1 wounds. All patients met discharge criteria on post-operative day 1. There was one post-operative wound occurrence which was a seroma. There were no infectious complications and no hernia recurrences. The average follow up was 1.4 ± 1.2 months.
CONCLUSIONS: Preperitoneal cross-over during eTEP ventral hernia technique is a safe technique that allows placement of a large extra-peritoneal mesh. Early patient outcomes are favorable. Larger sample size and follow-up are needed to truly assess postoperative outcomes.
The invention relates to a pharmaceutical composition for treating infantile splenic asthenia and moist heat diarrhea (spleen invigorating and diarrhea arresting pharmaceutical composition) and preparation method thereof. The pharmaceutical composition is prepared from the raw materials including codonopsis pilosula, lotus seed, white hyacinth bean, rhizoma coptidis, Baical Skullcap Root, honeysuckle, massa medicata fermentata, hawthorn, plantain seed and dried ginger. The preparation method comprises: adding water into and then boiling the codonopsis pilosula and other nine raw materials; combining the water solutions, filtering the combined water solution, subjecting a filtrate to vacuum concentration to 144 to 904ml, cooling the filtrate, adding ethanol having the same volume as the filtrate into the filtrate, mixing the mixed solution uniformly, standing the mixed solution for 12 to 24 hours and filtering the mixed solution; after recovery of ethanol, condensing the filtrate and obtaining a clear paste with a specific density of 1.15 to 1.25 (50 to 60 DEG C); adding medicinal accessories into the clear paste, mixing the mixture uniformly and making the mixture into grains; and drying the grains to obtain the pharmaceutical composition. The mixing ratio of crude drugs of the pharmaceutical composition is obtained through scientific selection. The pharmaceutical composition has efficacies of reducing fever and dehumidification, and invigorating spleen and arresting diarrhea and is used for treating infantile splenic asthenia and moist heat diarrhea and addresses both the symptoms and root cause. The spleen invigorating and diarrhea arresting drug prepared by the method improves the utilization rate of active ingredients, can be absorbed completely by human bodies, improves drug effect and is optimal for clinic application.
Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
A composition for treating or preventing restenosis after surgery is provided to suppress the proliferation of vascular smooth muscle cells (VSMCs) and prevent or treat restenosis and arteriosclerosis. A composition for preventing or treating restenosis comprises a compound of the chemical formula 1. The composition has the effect for preventing or treating cardiovascular diseases. The cardiovascular diseases are heart failure, hypertensive heart diseases, arrhythmia, congenital heart disease, and myocardial infarction. The composition is made in the form of liquid, emulsion, suspension, or cream and used by parenteral administration. A drug delivery apparatus for topical administration is a stent on which the composition is applied. The stent is a sustained-release stent.
The dose escalation was carried out according to the principle of "3 + 3" increase. Four dose levels (calculated by the number of tcr-t positive cells) were set up: the dose level was 1: 5 × 108 ± 30%; the dose level was 2: 2 × 109 ± 30%; the dose level was 3: 5 × 109 ± 30%; the dose level was 4: 1.2 × 1010 ± 30%. Three patients in the first group, if there is no DLT, they will be enrolled in the next higher dose group; if one of the three patients in a certain dose group has DLT, three patients in the group will be supplemented with the same dose and method. If DLT occurred in 1 or more of the 3 cases, the dose increase was stopped. The former dose was defined as MTD; if DLT did not occur in 3 cases, the dose increased to the next group. Dose escalation is not allowed for the same patient.
An integrated Community-based package of interventions An integrated intervention consisting of behaviourchange communication, and male involvement will be delivered to pregnant women in their third trimester. They will receive 2 prenatal and five home visits. each visit will last 40-60 minutes. After delivery mother-newborn pairs will be followed up until six weeks.
It is a prospective, randomized trial to determine whether the use of sonographic parameters during childbirth results in less intrapartum infection compared to traditional invasive examination. Intrapartum non-invasive ultrasound has been established and validated as a method of assessing labor progress. Guidelines from international societies recommend the use of ultrasound to monitor labor and support decision-making during delivery. Despite its reproducibility and reliability, there is no comprehensive work to date demonstrating the potential benefit in reducing clinical chorioamnionitis compared to traditional invasive vaginal examination. With this in mind, the investigators set out to analyze the clinical benefit of using ultrasound alone using established non-invasive, intrapartum, translabial parameters (Angle of Progression, Head Perineum Distance, Midline Angle, Cervix Dilatation) to monitor birth outcomes compared to traditional invasive vaginal examinations.

Primary Outcome is the incidence of clinical chorioamnionitis. Secondary Outcome measures include mode of delivery and neonatal outcomes such as neonatal admission.
FIELD: medicine, pharmacy. SUBSTANCE: method involves an aqueous-saline extraction of allergen solution from culture of mites of genus Dermatophagoides farinae, centrifugation of allergenic extract, sterilizing filtration of mother allergen solution, eight-fold tenth dilution of mother allergen solution with ethyl alcohol solution, applying prepared dilutions on sugar granules impregnated preliminary with 45% ethyl alcohol, periodic shaking granules for 10-15 min and drying sugar granules with medicinal preparation up to complete alcohol evaporation. Invention provides creature of effective and suitable in application granulated medicinal form from allergen of mites of genus Dermatophagoides farinae. Invention can be used for preparing oral granulated medicinal form from allergen from mites Dermatophagoides farinae. EFFECT: improved preparing method. 1 ex
FIELD: medicine. ^ SUBSTANCE: antagonistic activity of lactobacterium and/or bifidobacterium is determined simultaneously by method of double-layer agar and method of inverted agar, inoculation being performed by Gold. Power of antagonistic impact of probiotic strains of opportunistic microorganisms (OM) in comparison with control is estimated by degree of strain inhibition intensity. Antagonistic activity of probiotics is detected by one or two of said methods. In case of individual detection of antagonistic activity of probiotic medications, containing lactobacteria, in case of absence of antagonistic activity or detection of low or medium degree of intensity of OM inhibition, antagonistic activity is additionally detected by drop method. ^ EFFECT: increase of method accuracy and extension of spectrum of optimally selected probiotic medications for particular patient, simplification of inoculation and account of obtained result. ^ 2 cl,3 dwg, 10 tbl
PURPOSE:To provide a deodorizing composition effective remarkably to a sulfur- containing or nitrogen-contaning ill odor compound, and to provide a cake containing said composition and effective to eliminate foul breath, by extracting the fermented leaf of a plant of Theaceae family, and using the extract as an active component. CONSTITUTION:The cells of the leaf of Theaceae family plant are crushed, and are subjected to the enzymatic treatment with various oxidases of the plant in contact with air until the browning of the product takes place. The product, such as black tea, Oolong tea, etc. is extracted with a polar solvent such as hot water, aliphatic lower alcohol, ketone compound, etc. The extract is used as an active component of the objective deodorizing composition, and the composition is added to a cake such as chewing gum, candy, etc. to obtain the objective cake for eliminating foul breath.
Provided is a system (10) for determining a probability of an asthma exacerbation in a subject. The system comprises a first inhaler (100) for delivering a rescue medicament to the subject. The rescue medicament may be suitable for treating the subject's acute respiratory disease, for example by effecting rapid dilation of the bronchi and bronchioles upon inhalation of the medicament. The first inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation. A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue and/or routine inhalations. The processor then determines, using a weighted model, the probability of the asthma exacerbation based on the number of rescue inhalations and the parameters. The model is weighted such that the number of rescue inhalations is more significant in the probability determination than the parameters. Further provided is a method for determining the probability of an asthma exacerbation in a subject, which method employs the weighted model.
Each patient was educated about the benefits of PhA in PAH on the initial visit. Patients wore pedometers (Omron HJ-321-E) for 2 weeks. After PhA assessment, the patients were contacted by a physician. Patients who walked \<5,000 steps per day were recommended to increase PhA, and patients who walked ≥5,000 steps per day were recommended to maintain PhA. Patients wore pedometers for 3 months until their next visit. The primary endpoint was the number of steps after 12 weeks of the study; the secondary endpoint was the 6-minute walk test distance (6MWD), quality of life (SF-36), acceptance of the disease, and anxiety and depression level (HADS).
Thirteen patients (5 females, 8 males; mean age, 18.07±6.74 years) with healthy permanent dentition requiring the extraction of maxillary first premolars were included in a split-mouth randomized clinical trial. Subjects with previous orthodontic or endodontic treatment of canines were excluded. At least 3 months post-extraction, MOPs, and corticotomies were performed distal to the canines. Mini-screws with closed-coil springs (150g) were used for canine retraction. Dental casts were attained at baseline (T0) and 3 months post-intervention (T1). Calibrated examiners measured the distances from the canine to the second premolar on both sides. A Signed-rank sum test was used to compare canine retraction achieved in 3 months (T0-T1) in two sides
1,186,636. Anaplasmosis vaccine. DIAMOND LABORATORIES and UNIVERSITY OF ILLINOIS FOUNDATION. 30 May, 1968, No. 26021/68. Heading A5B. Anaplasmosis vaccine comprising an avirulent Anaplasma marginale mutant in a red blood cell carrier selected from the red blood cells of cattle, deer, sheep and goats may be prepared by exposing virulent Anaplasma margiriale to an amount of radiation sufficient to accelerate the rate of dissociation of the virulent Anaplasma marginale and to permit the selection of an avirulent form of this organism, passing the irradiated Anaplasma marfinale through the blood of at least one non- bovine ruminant host, and withdrawing blood of at least one host with the attentuated organism for use as said vaccine. The irradiated Anaplasma marginale may be serially passed through the blood of a plurality of non-bovine ruminant hosts. The radiation used may be X-ray or cobalt 60 radiation. The blood may be stored .under preserving conditions e.g. by desiccating the vaccine in admixture with polyvinylpyrrolidone, or by freezing the vaccine in admixture with glycerol. The withdrawn blood (with the addition of a clotting-preventing agent e.g. heparin) may be freeze-dried or frozen and the powder or frozen liquid respectively is stored. The vaccine may further comprise. a stabilizer e.g. polyvinyl pyrrolidone. The anaplasmosis vaccine may be suspended in sterile water or it may be in dry powdered or frozen liquid form.
Repair of inguinal hernia in one of the most frequently performed surgical operation in western world. The technique of choice is currently to support inguinal tissues by using polypropylene mesh. Chronic postoperative pain and discomfort occur in 25-30% of patients after inguinal hernioplasty. Pain might be related to mesh fixation by sutures. This randomized study investigates whether mesh fixation by tissue glue (cyanoacrylate) is better than sutures. The patients are followed 1 year postoperatively. Pain, quality of life, operative parameters (time, cost) and recurrences are reported.
FIELD: medicinal biochemistry. SUBSTANCE: method involves preliminary determination of D-mannose, L-fucose, D-ribose, D-2-deoxyribose, L-arabinose content in blood. After decrease of these indices bifidobacteria were added to diet after eating (1-4 times per a month) at restricted cow milk intake and dairy products and wheat product processing also, and their combinations. According the second variant, deficient monosugars or their mixtures at amount 0.001-1.0 g were administrated additionally (as pure substances, powder, tablets, syrups). Method can be used for prophylaxis and treatment of diseases caused by biochemical processes impairment in human organism. EFFECT: enhanced effectiveness of method.
Overdosage with tolterodine tartrate extended-release capsules can potentially result in severe central anticholinergic effects and should be treated accordingly.

ECG monitoring is recommended in the event of overdosage. In dogs, changes in the QT interval (slight prolongation of 10% to 20%) were observed at a suprapharmacologic dose of 4.5 mg/kg, which is about 68 times higher than the recommended human dose. In clinical trials of normal volunteers and patients, QT interval prolongation was observed with tolterodine immediate release at doses up to 8 mg (4 mg bid) and higher doses were not evaluated [see WARNINGS AND PRECAUTIONS (5.9) and CLINICAL PHARMACOLOGY (12.2)].

A 27-month-old child who ingested 5 to 7 tolterodine immediate release 2 mg tablets was treated with a suspension of activated charcoal and was hospitalized overnight with symptoms of dry mouth. The child fully recovered.
Participants will receive pembrolizumab (Keytruda) 200 mg administered by IV infusion every 3 weeks. Participants will remain on study and receive pembrolizumab for the nominal duration of treatment (35 cycles, approximately 2 years) or until there is evidence of disease progression by RECIST, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason.
OBJECTIVES: There remains debate over the optimal mitral valve replacement (MVR) option for patients aged 50-70 years. The objective of this study was to retrospectively compare the long-term outcomes of mechanical and bioprosthetic MVR in this patient population.
METHODS: Data from patients undergoing MVR between 2004 and 2018 were retrospectively reviewed. The primary outcome was all-cause mortality. Secondary outcomes included perioperative and late morbidity.
RESULTS: Two hundred and eight-six propensity-matched patients (n = 143 mechanical; n = 143 bioprosthetic) aged 50-70 years were included in the final analysis. Maximum follow-up was 15.8 years. There was no significant difference in all-cause mortality between the groups at 30 days, 1 year, 5 years, 10 years, and at the longest follow-up. Patients who underwent mechanical MVR experienced significantly lower rates of postoperative atrial fibrillation (P = 0.001). There were no significant differences in rates of sepsis, acute kidney injury, superficial and deep sternal wound infection, mediastinal bleeding, and permanent pacemaker implantation. At the longest follow-up, there were no differences in myocardial infarction, stroke, heart failure or overall rehospitalization. At the same time point, there was an increased rate of MVR in patients receiving a bioprosthetic valve (P = 0.015).
CONCLUSIONS: Survival following mechanical and bioprosthetic MVR in patients 50-70 years of age is similar to up to 15 years of follow-up. Bioprosthetic MVR is associated with an increased risk of repeat MVR. Mechanical MVR is not associated with an increased risk of stroke. Valve selection in this patient population requires diligent consideration of structural valve deterioration and subsequent reoperation risk as well as bleeding and thromboembolic risk.
PROBLEM TO BE SOLVED: To obtain an expected medical effect by adjusting the dissolved oxygen content and oxidation-reduction potential of the electrolytic water to specified values or less respectively. SOLUTION: The dissolved oxygen content and oxidation-reduction potential of this electrolytic water are adjusted to <=3.0ppm, preferably <=2.0ppm and more desirably <=1.0ppm and to <=-300mV, preferably <=-500mV and more desirably <=-700mV, respectively. As the electrolytic water production equipment, e.g. an equipment in which an electrolytic tank 1 is divided into an electrolytic room 5 and another electrolytic room 6 with a diaphragm 4 placed in the central part of the electrolytic tank 1, is used. Also, a voltage is applied to between two electrode plates 2 and 3 so that the current passing through an electrolyte between the electrode plates 2 and 3 is constant to perform electrolysis. As each of the electrode plates 2 and 3 placed in the electrolytic tank 1, a platinum plated titanium plate is used.  Thus, since the dissolved oxygen content in the electrolytic water is remarkably low, drinking water with which the amount of active oxygen that is a by-product of a metabolism utilizing an enzyme can be reduced and any oxidation of genes and cells can be inhibited from occurring, is produced.
Fentanyl buccal tablet is an opioid agonist, intended for buccal mucosal administration.

Fentanyl buccal tablet is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.

Fentanyl buccal tablet employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.

Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic solvents and sparingly soluble in water (1:40). The molecular weight of the free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens are 7.3 and 8.4. The compound has the following structural formula:

All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.

Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate, sodium carbonate, citric acid, and magnesium stearate.